Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells 41,312 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CEO Sean Nolan sold 41,312 shares of Taysha Gene Therapies stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $190,448.32. Following the sale, the chief executive officer directly owned 2,908,257 shares in the company, valued at $13,407,064.77. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Taysha Gene Therapies Trading Up 0.8%

Shares of NASDAQ TSHA traded up $0.04 during midday trading on Tuesday, reaching $4.76. The stock had a trading volume of 1,384,585 shares, compared to its average volume of 2,812,476. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -14.42 and a beta of 1.02. The company’s 50 day moving average price is $5.08 and its 200 day moving average price is $4.07. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. As a group, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on TSHA. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Chardan Capital restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Citizens Jmp boosted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 5th. Finally, UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently modified their holdings of TSHA. Marex Group plc purchased a new position in Taysha Gene Therapies in the 2nd quarter worth about $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the second quarter valued at approximately $31,000. ST Germain D J Co. Inc. grew its stake in shares of Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after acquiring an additional 4,333 shares during the last quarter. May Hill Capital LLC purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at $40,000. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.